Clinical trials: Essential,Hypertension
Essential Hypertension
Safety and Efficacy of Modulated Ultrasound Renal Denervation for HTN（FIM）
This study is a prospective and exploratory clinical study, enrolling patients with essential hypertension. This study is planned to be conducted in 2 research institutions in China, and a total of 6 subjects are planned to be…
- Trial name
- ModulationHTN1 (NCT06877234)
- Testing
- Ultrasonic Nerve Ablation System
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shenzhen Pulsecare Medical Technology Co., Ltd.
Essential Hypertension
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
This study was a non-interventional, secondary use of data, retrospective, cohort study, and the data to be extracted in this study was used as secondary use of collected patient information in the database (Japan Medical Data…
- Trial name
- NCT06604897
- Where
- United States
- Volunteers
- 1,405 people
- Sponsor
- Novartis Pharmaceuticals
Uncomplicated Hypertension, Hypertension
The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients
The sustained reduction in elevated blood pressure and lower incidence of adverse events of Lacidipine may provide additional benefits for hypertension patients than other CCBs (calcium channel blockers).
- Conditions
- Uncomplicated Hypertension, Hypertension, Essential
- Trial name
- NCT00338338
- Testing
- Lacidipine 4 or 6 mg (oral), Amlodipine 5 or 10 mg(oral)
- Where
- Taiwan
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Essential Hypertension
A Study to Evaluate the Pharmacokinetic Drug Interaction After Oral Concurrent Administration of Fimasartan and Amlodipine in Healthy Male Volunteers
To evaluate the pharmacokinetic drug interaction after oral concurrent administration of fimasartan and amlodipine in healthy male volunteers
- Trial name
- NCT00938197
- Testing
- Fimasartan, Amlodipine
- Where
- South Korea
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension
To determine whether impedance cardiography (ICG) parameters can predict favorable or unfavorable blood pressure (BP) response and time to BP control prior to initiation or intensification of specific antihypertensive drug…
- Trial name
- BETTER-HTN (NCT00913094)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- CardioDynamics
Essential Hypertension
Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS
A multicenter, Randomized, Double-blind, Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients with Essential Hypertension Inadequately Controlled with AGLS
- Trial name
- NCT05503953
- Testing
- AGSAVI, AGLS
- Where
- South Korea
- Volunteers
- 318 people
- Sponsor
- Ahn-Gook Pharmaceuticals Co.,Ltd
Essential Hypertension
Dose-finding Study With ACT-132577 (Aprocitentan) in Participants With Essential Hypertension
The main objective will be to evaluate the dose-response of ACT-132577 (aprocitentan) on diastolic blood pressure (DBP) in participants with grade 1 or 2 essential hypertension.
- Trial name
- NCT02603809
- Testing
- Aprocitentan 5 mg, Aprocitentan 10 mg, Aprocitentan 25 mg
- Where
- 90 sites in United States, Canada and 2 more
- Volunteers
- 1,659 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Essential Hypertension
Monitoring the Effectiveness and Safety of Antihypertensive Therapy With a Fixed-Dose Combination of Perindopril and Amlodipine in Patients With Uncontrolled Essential Hypertension
The aim of this observational study is to monitor the effectiveness of therapy, adherence and safety of a fixed combination of perindopril + amlodipine in patients with essential hypertension.
- Trial name
- NCT07876895
- Testing
- fixed combination of perindopril + amlodipine
- Where
- Bosnia and Herzegovina
- Volunteers
- 600 people
- Sponsor
- Bosnalijek D.D
Hypertension (HTN), NYHA Class III Heart Failure
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
Objective: This study aims to evaluate the safety and efficacy of the fixed-dose triple combination therapy (SPC1001 Low) of candesartan, amlodipine, and indapamide in adult patients with essential hypertension compared to…
- Conditions
- Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure, Diabete Mellitus
- Trial name
- NCT07064525
- Testing
- SPC1001 Low, SPC5002, SPC5003
- Where
- South Korea
- Volunteers
- 252 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Healthy Volunteers Essential Hypertension
Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension
Part 1 : To evaluate the safety of single-dose KK3910 in healthy volunteers. Part 2 : To evaluate the safety of multiple-dose KK3910 in patients with essential hypertension.
- Trial name
- NCT06823947
- Testing
- KK3910
- Where
- 3 sites in Japan
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Kyowa Kirin Co., Ltd.
Hypertension,Essential
First-In-Human Study Evaluating a Novel Catheter Device in Subjects With Treatment-Resistant Hypertension
The carotid body is located at the bifurcation of the internal and external carotid arteries. It is a chemoreceptor that plays a role in the sympathetic nervous system and in the development and maintenance of hypertension.
- Trial name
- NCT03314012
- Testing
- Catheter-Based Carotid Body Ablation
- Where
- 7 sites in Australia, Czechia and 1 more
- Volunteers
- 39 people
- Sponsor
- Cibiem, Inc.
Hypertension
Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension
Study of the efficacy and tolerance of Motens® (lacidipine) in patients with essential hypertension. To obtain information on the dosage used in practice and the tolerance at the start of treatment (12 weeks)
- Trial name
- NCT02235415
- Testing
- Motens® (lacidipine)
- Volunteers
- 24,526 people
- Sponsor
- Boehringer Ingelheim
Hypertension
Impact of MK-0954A on Uric Acid in the Management of Hypertension (MK-0954A-366)
This was a retrospective, chart review, observational study to assess the effect of MK-0954A (losartan potassium 50 mg + hydrochlorothiazide 12.5 mg [Hyzaar(R)]) treatment for a period of at least three months on serum uric acid…
- Trial name
- NCT01368185
- Volunteers
- 1,705 people
- Sponsor
- Organon and Co
Essential Hypertension, Hyperlipidemia
Study to Investigate the Effect of Telmisartan/S-amlodipine on the Pharmacokinetic Properties of Atorvastatin.
The purpose of this study is to investigate the effect of telmisartan/s-amlodipine on the pharmacokinetic properties of atorvastatin.
- Trial name
- CKD-345 (NCT01842256)
- Testing
- Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg, atorvastatin 40mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hypertension
BP-EASE -Effectiveness of Losartan 50 mg/Hydrochlorothiazide (HCTZ) 12.5 mg Versus Valsartan 80 mg/HCTZ 12.5 mg Titrated as Needed in Patients With Essential Hypertension Not Controlled on Monotherapy (0954A-333)
To evaluate the blood pressure efficacy between losartan and valsartan at equivalent dosage during a 3 months treatment.
- Trial name
- EASE (NCT00546754)
- Testing
- losartan potassium (+) hydrochlorothiazide, Comparator: Valsartan (+) Hydrochlorothiazide
- Volunteers
- 808 people
- Sponsor
- Organon and Co
Hypertension
Study to Evaluate the Efficacy and Safety of Combination Aliskiren/Amlodipine in Patients Not Adequately Responding to Aliskiren Alone
This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients not adequately controlled with aliskiren alone
- Trial name
- NCT00777946
- Testing
- Aliskiren 300 mg, Aliskiren/Amlodipine 300/5 mg, Aliskiren/Amlodipine 300/10 mg
- Where
- 9 sites in Estonia, France and 7 more
- Volunteers
- 818 people
- Sponsor
- Novartis
Hypertension, Essential, Primary Hypercholesterolemia
Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
The purpose of this study is to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
- Trial name
- NCT06448962
- Testing
- AD-2021, AD-2022
- Where
- South Korea
- Volunteers
- 109 people
- Sponsor
- Addpharma Inc.
Essential Hypertension
Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.
The purpose of this study is to investigate the efficacy (blood pressure lowering effect) and safety of aliskiren given to hypertensive patients after a missed dose.
- Trial name
- NCT00343551
- Testing
- Aliskiren
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 654 people
- Sponsor
- Novartis
Essential,Hypertension
Fimasartan Achieving SBP Target (FAST) Study
The purpose of this study is to evaluate the efficacy and safety of Fimasartan compared to Valsartan and Olmesartan(reference group) in patients with mild to moderate essential hypertension.
- Trial name
- FAST (NCT02495324)
- Testing
- Fimasartan, Valsartan, Olmesartan medoxomil
- Where
- 8 sites in South Korea
- Volunteers
- 369 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension
A Long Term Study of SPP100 in Patients With Essential Hypertension (Trial is Not Recruiting in the US)
This study will evaluate the safety and efficacy of long term treatment of SPP100 in patients with essential hypertension. (Trial is not recruiting in the US)
- Trial name
- NCT00246584
- Testing
- SPP100
- Where
- Switzerland
- Volunteers
- 300 people
- Sponsor
- Novartis